Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Not Confirmed
Not Confirmed
11-13 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Industry Trade Show
Not Confirmed
11-13 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
Details:
Through MOU, Prestige and Vaxine will be building a partnership, initially focused on manufacturing and commercialization of Vaxine’s Covid-19 vaccine, Covax-19® and then as Covid-19 enters an endemic phase development of a next generation Covid19/influenza combo vaccine.
Lead Product(s): Covax-19
Therapeutic Area: Infections and Infectious Diseases Brand Name: Spikogen
Study Phase: ApprovedProduct Type: Vaccine
Recipient: Prestige BioPharma Pte Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 30, 2022
Lead Product(s) : Covax-19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Recipient : Prestige BioPharma Pte Ltd
Deal Size : Undisclosed
Deal Type : Agreement
Details : Through MOU, Prestige and Vaxine will be building a partnership, initially focused on manufacturing and commercialization of Vaxine’s Covid-19 vaccine, Covax-19® and then as Covid-19 enters an endemic phase development of a next generation Covid19/inf...
Brand Name : Spikogen
Molecule Type : Vaccine
Upfront Cash : Undisclosed
March 30, 2022
Details:
SpikoGen features the SARS-CoV-2 spike protein and Vaxine’s own Advax-SM adjuvant. The placebo-controlled SpikoGen trial has coprimary endpoints investigating the occurrence of symptomatic Covid-19 and severe Covid-19, with both endpoints.
Lead Product(s): SARS-CoV-2 Recombinant Spike Protein,Advax-SM
Therapeutic Area: Infections and Infectious Diseases Brand Name: SpikoGen
Study Phase: Phase IIIProduct Type: Vaccine
Recipient: CinnaGen Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2021
Lead Product(s) : SARS-CoV-2 Recombinant Spike Protein,Advax-SM
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : CinnaGen Co
Deal Size : Not Applicable
Deal Type : Not Applicable
CinnaGen Protein Subunit Covid-19 Vaccine Phase III Results Likely Within Two Months
Details : SpikoGen features the SARS-CoV-2 spike protein and Vaxine’s own Advax-SM adjuvant. The placebo-controlled SpikoGen trial has coprimary endpoints investigating the occurrence of symptomatic Covid-19 and severe Covid-19, with both endpoints.
Brand Name : SpikoGen
Molecule Type : Vaccine
Upfront Cash : Not Applicable
September 16, 2021
Details:
The collaboration aims at developing a Covid-19 vaccine called, COVAX-19®, which is currently undergoing late stage animal testing and is based on Vaxine’s proprietary Advax™ adjuvant technology combined with a recombinant SARS-CoV-2 spike protein.
Lead Product(s): COVAX-19
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Vaccine
Sponsor: Medytox
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 25, 2020
Lead Product(s) : COVAX-19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Medytox
Deal Size : Undisclosed
Deal Type : Collaboration
Vaxine and Medytox partner on Covid-19 vaccine development
Details : The collaboration aims at developing a Covid-19 vaccine called, COVAX-19®, which is currently undergoing late stage animal testing and is based on Vaxine’s proprietary Advax™ adjuvant technology combined with a recombinant SARS-CoV-2 spike protein.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
May 25, 2020
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?